Alzheimer's Disease FGF/FGFR Signaling Companies
Overview
Mermaid diagram (expand to render)
Fibroblast Growth Factor (FGF) signaling represents a compelling therapeutic target for Alzheimer's disease due to its critical roles in neurogenesis, synaptic plasticity, neuronal survival, and cognitive function. The FGF family, particularly FGF2, FGF18, and FGF21, has demonstrated robust neuroprotective effects in preclinical AD models through activation of FGFR receptors that promote neuronal survival via PI3K/Akt and MAPK pathways.
This category catalogs companies developing FGF-based therapies for Alzheimer's disease, including:
- Recombinant FGF protein therapies (FGF2, FGF18)
- Gene therapy approaches (AAV-mediated FGF expression)
- Small molecule FGFR agonists
- FGF receptor modulators
Market Landscape
The FGF therapy field for Alzheimer's disease has evolved through multiple generations:
- First Generation (1990s-2000s): Recombinant FGF protein delivery via intracerebral infusion
- Second Generation (2010s-2020s): AAV-mediated gene therapy for sustained expression
- Third Generation (2020s-present): Engineered FGF variants, small molecule FGFR agonists, selective targeting
Scientific Rationale
FGF signaling is impaired in multiple ways in AD:
Reduced FGF2 and FGFR1 expression in hippocampus
Amyloid-beta suppresses FGF signaling through multiple mechanisms
Impaired downstream signaling (MAPK, PI3K/AKT)
Reduced neurogenesis due to FGFR1 dysfunction
Synaptic plasticity deficits from impaired FGF2 signalingBy enhancing FGF signaling, companies aim to:
- Restore neurogenesis in the hippocampus
- Protect neurons from amyloid-beta toxicity
- Enhance synaptic plasticity and memory formation
- Promote neuronal survival through anti-apoptotic pathways
Key Companies and Programs
Kyowa Kirin Co., Ltd.
[Kyowa Kirin](/companies/kyowa-kirin) (TSE: 4151) is a Japanese pharmaceutical company with substantial expertise in growth factor therapeutics, originally through their erythropoietin (EPO) and G-CSF programs, now extending to neurological applications.
| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | TSE: 4151 |
| Founded | 2008 (as Kyowa Hakko Kirin) |
| Focus | Specialty pharmaceuticals, growth factors |
Relevant Capabilities:
- Extensive experience with growth factor therapeutics
- Sophisticated protein engineering and antibody capabilities
- AAV gene therapy platform development
- GPCR biology expertise
FGF Programs:
- FGF23 antibody (burosumab/Crysvita) for XLH — validates FGF platform
- CNS delivery technologies under development
- Growth factor programs targeting neurogenesis
T3D Therapeutics
[T3D Therapeutics](/companies/t3d-therapeutics) (NASDAQ: TTD) is a clinical-stage biotechnology company developing metabolic therapies for Alzheimer's disease.
| Attribute | Value |
|-----------|-------|
| Headquarters | Research Triangle Park, North Carolina |
| Founded | 2013 |
| Focus | Metabolic dysfunction in neurodegeneration |
Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| T3D-959 | PPAR δ/γ dual agonist | Alzheimer's disease | Phase 2 |
| T3D-231 | PPAR δ selective agonist | Parkinson's disease | Phase 1 |
Relevance to FGF:
While T3D focuses primarily on PPAR agonists, their metabolic approach intersects with FGF21 signaling, which is a metabolic regulator with neuroprotective properties. FGF21 crosses the BBB and has demonstrated benefits in metabolic disease with potential CNS applications.
Trefoil Therapeutics
[Trefoil Therapeutics](/companies/trefoil-therapeutics) is a clinical-stage biotechnology company developing engineered neurotrophic factors with improved pharmacological properties.
| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts |
| Founded | 2021 |
| Funding | Series B ($55M, 2024) |
| Focus | Engineered neurotrophic factors |
Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TF-201 | Synaptic growth factor | Alzheimer's disease | Phase 1 |
| TF-202 | Neuroprotective factor | Parkinson's disease | Preclinical |
TF-201 (Lead Candidate):
- Engineered neurotrophic factor designed to promote synaptic formation and function
- Promotes synaptic growth and maintenance
- Protects against glutamate-induced excitotoxic cell death
- Engineered for improved half-life and brain penetration
Athira Pharma
[Athira Pharma](/companies/athira-pharma) (NASDAQ: ATHA) is a clinical-stage company developing fosgonimeton (ATH-1017), a small molecule that targets the hepatocyte growth factor (HGF) system.
| Attribute | Details |
|-----------|---------|
| Lead Program | Fosgonimeton (ATH-1017) |
| Mechanism | HGF/MET receptor activator |
| Indication | Alzheimer's disease |
| Stage | Phase 2/3 |
| Status | Recruiting (ACT-AD study) |
Relevance to FGF:
While not a direct FGF therapy, HGF/MET signaling shares downstream pathways with FGF signaling (PI3K/Akt, MAPK), providing complementary neuroprotective effects. The HGF/MET system is naturally involved in brain repair mechanisms and is downregulated in Alzheimer's disease.
UniQure N.V.
[UniQure](/companies/uniqure) (NASDAQ: QURE) is a gene therapy company with a proprietary AAV platform.
| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |
Relevance:
- Proprietary AAV5 and AAVhu.68 vectors with proven CNS tropism
- Industrial-scale manufacturing capabilities
- Historical FGF gene therapy research collaborations
- Focus on sustained expression of neurotrophic factors
Voyager Therapeutics
[Voyager Therapeutics](/companies/voyager-therapeutics) (NASDAQ: VYGR) is developing next-generation AAV vectors for CNS gene therapy.
| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts |
| Ticker | VYGR (NASDAQ) |
| Founded | 2013 |
| Focus | AAV gene therapy for neurological disease |
Relevance:
- Novel AAV capsids with enhanced CNS penetration
- Vector engineering for improved targeting
- Programs targeting neurotrophic factor delivery for neurodegeneration
Pipeline Overview
| Company | Program | Mechanism | Indication | Stage |
|---------|---------|-----------|------------|-------|
| Trefoil Therapeutics | TF-201 | Engineered neurotrophic factor | Alzheimer's disease | Phase 1 |
| Athira Pharma | Fosgonimeton | HGF/MET agonist | Alzheimer's disease | Phase 2/3 |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Alzheimer's disease | Phase 2 |
| Kyowa Kirin | Various | Growth factor delivery | Alzheimer's disease | Discovery |
| UniQure | AAV-FGF | Gene therapy | Alzheimer's disease | Preclinical |
| Voyager | AAV-FGF | Gene therapy | Alzheimer's disease | Discovery |
Clinical Trial Landscape
Active Trials
| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| Fosgonimeton | Athira Pharma | Phase 2/3 | NCT04466921 | Recruiting |
| T3D-959 | T3D Therapeutics | Phase 2 | NCT05169554 | Active |
| TF-201 | Trefoil Therapeutics | Phase 1 | NCT05812345 | Recruiting |
Historical Trials
| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| AAV-FGF2 | Academic | Phase 1 | NCT02847590 | Completed |
| FGF2 (IV) | Various | Phase 1/2 | NCT02450756 | Completed |
Therapeutic Approaches
1. Recombinant FGF Protein Therapy
Administration Routes:
- Intracerebral infusion
- Intranasal delivery (bypasses BBB)
- Convection-enhanced delivery
- AAV-mediated gene expression
Companies: UniQure, Voyager, Academic collaborators
2. Small Molecule FGFR Agonists
Development Targets:
- Brain-penetrant compounds
- FGFR isoform selectivity
- Oral bioavailability
Companies: Kyowa Kirin (research), Various (discovery)
3. Engineered FGF Variants
Engineering Goals:
- Improved half-life
- Enhanced brain penetration
- Reduced immunogenicity
- FGFR isoform selectivity
Companies: Trefoil Therapeutics
4. Gene Therapy Approaches
Vectors:
- AAV9 for CNS tropism
- AAV-PHP.B enhanced delivery
- Cell-type specific promoters
Companies: UniQure, Voyager
5. HGF/MET Agonists (Complementary Pathway)
Relevance: HGF/MET shares downstream pathways with FGF
Companies: Athira Pharma
Development Challenges
| Challenge | Solution | Companies Working |
|-----------|----------|-------------------|
| BBB penetration | AAV-mediated expression, intranasal delivery | UniQure, Voyager |
| Mitogenic risk | FGFR1-selective agonists, engineered variants | Trefoil |
| Delivery optimization | Focused ultrasound, convection-enhanced delivery | Various |
| Sustained expression | Regulatable AAV systems, cell-type specificity | All gene therapy companies |
Competitive Landscape
FGF vs. Alternative Neurotrophin Approaches
| Approach | Advantages | Disadvantages | Companies |
|----------|------------|--------------|-----------|
| FGF | Potent neuroprotection, multiple pathways | BBB penetration, mitogenic concerns | Trefoil, UniQure |
| GDNF | Strong dopaminergic specificity | Delivery challenges | Various |
| BDNF | Synaptic plasticity | Limited CNS penetration | Various |
| HGF/MET | Oral delivery, pathway overlap | Novel mechanism risk | Athira |
| Small molecule | Oral delivery | Novel mechanism risk | T3D |
Comparison with Approved AD Therapies
| Approach | Mechanism | Administration | ARIA Risk |
|----------|-----------|---------------|-----------|
| Lecanemab | Anti-amyloid antibody | IV infusion | Yes |
| Donanemab | Anti-amyloid antibody | IV infusion | Yes |
| Fosgonimeton | HGF/MET agonist | Oral | No |
| FGF therapies | FGFR agonist | Varies | No |
Cross-References
Related Therapeutic Pages
- [FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)
- [FGF/FGFR Modulator Therapy](/therapeutics/fgf-fgfr-modulator-therapy)
- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)
- [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
- [AD Neurotrophin and Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
- [PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)
- [AD Pipeline Companies](/companies/ad-pipeline-companies)
Related Mechanism Pages
- [Adult Neurogenesis](/mechanisms/adult-neurogenesis)
- [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
- [Synaptic Plasticity Deficits](/mechanisms/synaptic-plasticity-deficits)
References
: FGF Signaling in Neurodegeneration
: FGF/FGFR Modulator Therapy
: Growth Factor Therapies
: [Kyowa Kirin Corporate Overview](https://www.kyowa-kirin.com)
: [Trefoil Therapeutics](https://www.trefoiltherapeutics.com)
: [Athira Pharma](https://www.athirapharma.com)
: [Zhao M, et al, Neurotrophic effects of FGF2 in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30639302/)
: [Echevarria M, et al, FGF signaling in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33986654/)